Company Performance Metrics
SBI Biotech mainly focuses on dendritic cell platform-based innovative drug development.
As an R&D-type bio-venture company, we do not have abundant human resource like in the case of general pharmaceutical companies and we mainly focus on our activity in the early stages of drug development. Particularly, our biggest hurdle is the clinical
studies / clincal trials which we need huge budgets to support our clinical trials on human to test drug safety and efficacy.
We have been trying to utilize our human and financial resources efficiently by early licensing of our pipelines in the preclinical stage, instead of performing the clinical trials by our own. For the early stage licensing, we have tried to provide excellent products by the world-leading research team with the expertise in dendritic cell manipulation. We have successfully proven the feasibility of the business model since we succeeded in licensing of our early stage dendritic cells targeting antibody, anti-ILT7 antibody to MedImmune. We will continue our efforts in early licensing activity by our highly competitive research team.
